Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00519090 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated due to limited enrollment.

Conditions

Myelogenous Leukemia

Interventions

DRUG: Imatinib
DRUG: Nilotinib (AMN107)

Sponsor

Novartis Pharmaceuticals